Global Leader in Digital Pathology AI Healthcare — aetherAI (7803) Officially Lists on the Taiwan Innovation Board

aetherAI: Delivering Integrated Software-and-Hardware Consulting Solutions for the Global Digital Transformation of Pathology — Growth Momentum Poised to Accelerate

aetherAI (7803), a global leader in digital pathology and AI healthcare solutions, officially began trading on the Taiwan Innovation Board on May 20 at an offering price of NT$23.12 per share. A listing ceremony and opening bell event were held at the Taiwan Stock Exchange Information Display Center. aetherAI is Taiwan’s first digital pathology AI company to enter the capital markets, combining internationally competitive R&D capabilities with an integrated software-and-hardware digital pathology solution portfolio. Joe Yeh, Chairman and CEO of aetherAI, stated:

“aetherAI’s listing on the Innovation Board today marks an important milestone on our journey into the global capital markets. Since our founding, we have expanded from Taiwan into the EU, Japan, and North America, successfully leveraging the clinical benefits of AI-assisted diagnostics to accelerate the digital transformation of pathology. As global demand for digital pathology image analysis surges, aetherAI’s revenue is poised to enter a new phase of growth. Backed by our software-and-hardware integration strategy, which is driving market penetration, together with our continuously advancing R&D capabilities, we will deliver steady, long-term value for our investors.”

Global Digital Pathology Image Analysis Market to Grow at a CAGR of Over 9% — aetherAI Positioned to Ride the Wave

According to Mordor Intelligence’s Digital Pathology Image Analysis Market report, the global market is projected to grow steadily from US$458 million in 2026 to US$704 million by 2031, representing a compound annual growth rate (CAGR) of 9.03%. This growth is driven primarily by pathology departments’ accelerating adoption of AI tools to address an increasingly severe shortage of skilled professionals, reflecting clear, structurally supported demand. aetherAI’s core product, the aetherSlide digital pathology image management system, recently obtained EU IVDR certification, making it one of the few digital pathology image management systems in the world to hold both U.S. FDA clearance and EU IVDR certification. This milestone not only demonstrates that aetherSlide meets the most stringent international regulatory standards, but also establishes the compliance foundation for the company to enter the mature U.S. and European markets directly, positioning it to expand its commercial footprint in step with rapid market growth.

Advancing on Two Fronts — Software and Hardware Integration — to Open a Second Growth Curve in Pathology and Laboratory Medicine

In addition to major regulatory progress for its core product aetherSlide, aetherAI has also developed the aetherBot fully automated slide scanning system and the aetherScope fully automated AI bone marrow smear classification and counting system. These integrated software-and-hardware solutions target hospital pathology and laboratory medicine departments, addressing at the root the slide scanning, bone marrow smear scanning, and cell classification and counting processes that have long relied heavily on manual labor. aetherBot was co-developed by aetherAI, Hamamatsu Photonics — a global leader in digital pathology imaging and scanning systems — and Techman Robot, and automates the entire workflow of slide scanning, AI-based image quality auditing, and archiving. The collaboration also draws on Hamamatsu Photonics’ more than 20 years of brand presence and distribution channels in the U.S. and European healthcare markets to accelerate aetherAI’s overseas expansion. aetherScope integrates aetherAI’s Hema bone marrow smear AI classification software, targeting the laboratory medicine market as a strategic gateway into clinical laboratories. Together, these two automated products form the breakthrough point of aetherAI’s “software-led, hardware-enabled” strategy, using automated solutions as an entry point into overseas markets while, in turn, driving the penetration of the core aetherSlide platform abroad — providing the company with highly sticky, long-term recurring revenue momentum.

Two Proprietary Technologies, GigaPixel and Gaia, Accelerate Digital Adoption Among Small and Mid-Sized Pathology Labs

AI adoption in pathology typically takes years, owing to lengthy development timelines, substantial GPU resource requirements, and heavy reliance on specialized personnel for region-by-region image annotation. Many small and mid-sized pathology labs are constrained by both limited computing power and a lack of annotated datasets, leaving them unable to keep pace with digitalization. aetherAI’s two proprietary patented technologies remove these adoption barriers at the root, enabling the company to capture penetration among small and mid-sized pathology labs. The patented GigaPixel weakly-supervised algorithm requires only “slide-level” labeling — through this patented weakly-supervised training method, only slide-level labels are needed, eliminating time-consuming region-by-region annotation. Meanwhile, the Gaia foundation AI model was trained through self-supervised learning on nearly 100,000 whole-slide images aggregated from dozens of medical institutions worldwide, producing a large-scale pathology foundation model that spans countries, ethnicities, and institutions and reduces downstream AI training data requirements by 99%. Together, these two proprietary technologies form aetherAI’s technology moat, enabling more medical institutions to rapidly develop their own AI models. As adoption barriers fall sharply, aetherAI’s addressable market will expand from leading medical centers to a broad base of small and mid-sized medical institutions, driving further adoption of the aetherSlide platform and laying a long-term foundation for the company’s next wave of structural growth.

With the aetherBot and aetherScope automated software-and-hardware solutions serving as market entry points, and continued expansion into the small and mid-sized pathology lab market through the proprietary GigaPixel algorithm and Gaia foundation AI model, aetherAI expects to drive high-margin recurring revenue from aetherSlide platform adoption and AI module subscriptions. This is expected to strengthen the sustainability of the company’s profitability and further solidify aetherAI’s leadership position in the global digital pathology market, delivering steady and long-term investment value for shareholders.

aetherAI Media Contact: Director of Customer Solutions
Adam Yen, +886 912-337-903

SOURCE: aetherAI